Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haikun Shenxi Capsule plus SGLT-2 inhibitor in ESRD
ChiCTR2500101924Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Baotou Medical College
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of fucoidan and canagliflozin in end-stage kidney disease (ESKD) (3 arms), sponsored by The First Affiliated Hospital of Baotou Medical College. Primary endpoints: Blood Urea Nitrogen, Serum Creatinine and 11 more. Planned start May 2025; status: not yet recruiting.
02
Drugs
fucoidancanagliflozin
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on ChiCTR2500101924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101924.